Temocillin Treatment of Serious Infections due to Gram-Negative Bacilli in an Intensive Care Unit1

Lesage, D.; Hericord, P; Pinta, P.; Leauté, J. B.; Amstutz, P

doi:10.2165/00003495-198500295-00048

Cited by 6 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of this study cannot be compared with previous data from studies using the combination of piperacillin and tazobactam in the management of pneumonia because of differences in the criteria used for the selection of patients, type of antibiotic regimen prescribed in the control group, and variables analyzed [21,22,23,24,25,26] While some series [23,24] included all nosocomial pneumonias regardless of the location and the severity of the patient's condition, other studies only analyzed the pneumonias diagnosed during the mechanical ventilation and, in this latter case, even only those in which an etiological diagnosis was obtained by invasive methods [33]. In our study, those pneumonias diagnosed in services other than the ICU that required mechanical ventilation and those diagnosed during the stay in the ICU in patients with mechanical ventilation were included.…”

Section: Discussionmentioning

confidence: 91%

“…Piperacillin/tazobactam has been successfully used to treat severe nosocomial and community-acquired lower respiratory tract infections [21,22,23,24,25,26]. This study was conducted to compare clinical and bacteriological efficacy as well as tolerability of two regimens of broad-spectrum antibiotics, that is, ceftazidime versus piperacillin/tazobactam combined with amikacin in the treatment of nosocomial pneumonia in intensive care patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

et al. 2001

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

et al. 2001

View full text Add to dashboard Cite

show abstract

“…In a single Intensive Care Unit (ICU), Offenstadt et al reported 11 patients with UTI, including six with sepsis, being treated with temocillin. The most common bacteria isolated were Enterobacterales, mainly E. coli [46]. The clinical cure was achieved in six patients, two patients had clinical failure, and three patients died.…”

Section: Temocillin In Urinary Tract Infectionsmentioning

confidence: 98%

“…The clinical cure was achieved in six patients, two patients had clinical failure, and three patients died. Interestingly, in one of them, a second urine culture revealed the presence of P. aeruginosa [46]. The efficacy of temocillin in children with cUTI was retrospectively evaluated in 22 children with a mean age of 5.8 years.…”

Section: Temocillin In Urinary Tract Infectionsmentioning

confidence: 99%

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic

et al. 2022

View full text Add to dashboard Cite

Temocillin is an old antibiotic, but given its particular characteristics, it may be a suitable alternative to carbapenems for treating infections due to ESBL-producing Enterobacterales and uncomplicated UTI due to KPC-producers. In this narrative review, the main research question was to summarize current evidence on temocillin and its uses in infectious diseases. A search was run on PubMed using the terms (‘Temocillin’ [Mesh]) AND (‘Infection’ [Mesh]). Current knowledge regarding temocillin in urinary tract infection, blood-stream infections, pneumonia, intra-abdominal infections, central nervous system infections, skin and soft tissues infections, surgical sites infections and osteoarticular Infections were summarized. Temocillin retain a favourable profile on microbiota and risk of Clostridioides difficile infections and could be an option for treating outpatients. Temocillin may be a valuable tool to treat susceptible pathogens and for which a carbapenem could be spared. Other advantages in temocillin use are that it is well-tolerated; it is associated with a low rate of C. difficile infections; it is active against ESBL, AmpC, and KPC-producing Enterobacterales; and it can be used in the OPAT clinical setting.

show abstract

“…2 In France, temocillin obtained marketing authorization for the treatment of urinary tract infections in 2015 at the recommended dosages of 4-6 g per day and 25-50 mg/kg/24 h for adults or children with normal renal function, respectively. While some studies and data are available to support temocillin dosage in adults, [6][7][8][9] only a few case reports can be found for children. 10,11 We report herein a case of bacteraemic ESBL-producing Enterobacter cloacae urinary tract infection successfully treated with temocillin in a preterm infant with severe renal failure.…”

Section: Introductionmentioning

confidence: 99%

Temocillin dosage adjustment in a preterm infant with severe renal disease: a case report

Dumangin

Brenkman

Pape

et al. 2020

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Background Temocillin is a carboxypenicillin antibiotic indicated in complicated urinary tract infections due to susceptible ESBL-producing Enterobacteriaceae. While temocillin therapeutic schemes for adult patients with normal or impaired renal function are evidence based, little is known in paediatric populations. Objectives We report herein the management of temocillin treatment in a preterm infant with end-stage renal disease. Patients and methods The patient was a 7-month-old preterm infant born at 35 weeks gestation and treated by temocillin for 10 days for a bacteraemic urinary tract infection due to a susceptible ESBL-producing Enterobacter cloacae complex strain. Temocillin was administered by continuous infusion using a loading dose of 25 mg followed by a maintenance dose of 70 mg daily. Determination of MIC and temocillin plasma and urinary concentration was performed. Results Clinical improvement was observed 24 h after the initiation of temocillin treatment. Temocillin concentrations ranged between 21.6 and 35.5 mg/L in urine between the first and the sixth day of treatment and between 47.0 and 61.8 mg/L in plasma after 6 and 10 days of treatment, respectively. Temocillin concentrations were found to be above the determined MIC of 6 mg/L. From the measured concentrations, we can postulate that 100%fT>MIC was achieved in urine and at least equal to 40% in plasma. Conclusions Temocillin dosing adjustment performed in the present reported case allowed safe and effective treatment. The strategy described herein could be used as a basis for further clinical studies relative to temocillin use in a paediatric population with renal impairment.

show abstract

Temocillin Treatment of Serious Infections due to Gram-Negative Bacilli in an Intensive Care Unit1

Cited by 6 publications

References 3 publications

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic

Temocillin dosage adjustment in a preterm infant with severe renal disease: a case report

Contact Info

Product

Resources

About